Search ARM

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company founded in 2015 with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. Our TAC platform offers competitive advantages over CAR-T and TCR therapies, including: Co-opting the natural T cell signaling pathways; Design of a safer and more effective T cell therapy; Demonstration of superiority in preclinical models; A strong intellectual property platform including composition of matter applications, and freedom to operate; An expanding pipeline including solid and liquid tumor indications.

Contact Triumvira
Visit Website